Efficacy of instillations with chemotherapy or immunotherapy following endoscopic resection for upper tract urothelial carcinoma

References

• Lilienthal H. Nephroureterectomy: description of a simple and improved method. Ann. Surg.53(4), 521–524 (1911).
   PubMedGoogle Scholar
• Ercole R. Total nephroureterectomy in the treatment of papillary tumors of the renal pelvis. Rev. Argent. Urol.20(1–4), 71–77 (1951).
   PubMedGoogle Scholar
• De Wolf WC, Rodgers R, Blackard C. Conservative management of ureteral tumor. Urology4(1), 44–49 (1974).
   PubMedGoogle Scholar
• Johnson DE, Babaian RJ. Conservative surgical management for noninvasive distal ureteral carcinoma. Urology13(4), 365–367 (1979).
   PubMed Web of Science ®Google Scholar
• Huffman JL, Bagley DH, Lyon ES, Morse MJ, Herr HW, Whitmore WF Jr. Endoscopic diagnosis and treatment of upper-tract urothelial tumors. A preliminary report. Cancer55(6), 1422–1428 (1985).
   PubMed Web of Science ®Google Scholar
• Roupret M, Zigeuner R, Palou J et al. European guidelines for the diagnosis and management of upper tract urothelial carcinomas: 2011 update. Eur. Urol.59(4), 584–594 (2011).
   PubMed Web of Science ®Google Scholar
• Cai G, Liu X, Wu B. Treatment of upper urinary tract urothelial carcinoma. Surg. Oncol.20(1), 43–55 (2011).
   PubMedGoogle Scholar
• Cornu JN, Roupret M, Carpentier X et al. Oncologic control obtained after exclusive flexible ureteroscopic management of upper tract urothelial cell carcinoma. World J. Urol.28(2), 151–156 (2010).
   PubMed Web of Science ®Google Scholar
• Wolf JS Jr. Are we underutilizing minimally invasive approaches for upper tract urothelial carcinoma? Urol. Oncol.27(1), 75–80 (2009).
   PubMedGoogle Scholar
• Mitchell RJ. Intravesical thiotepa in the treatment of transitional cell bladder carcinoma. Br. J. Urol.43(2), 185–188 (1971).
   PubMedGoogle Scholar
• Riddle PR. The management of superficial bladder tumours with intravesical epodyl. Br. J. Urol.45(1), 84–87 (1973).
   PubMedGoogle Scholar
• Pinsky CM, Camacho FJ, Kerr D et al. Intravesical administration of bacillus Calmette–Guérin in patients with recurrent superficial carcinoma of the urinary bladder: report of a prospective, randomized trial. Cancer Treat. Rep.69(1), 47–53 (1985).
   PubMedGoogle Scholar
• Herr HW, Schwalb DM, Zhang ZF et al. Intravesical bacillus Calmette–Guérin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial. J. Clin. Oncol.13(6), 1404–1408 (1995).
   PubMed Web of Science ®Google Scholar
• Gupta R, Paner GP, Amin MB. Neoplasms of the upper urinary tract: a review with focus on urothelial carcinoma of the pelvicalyceal system and aspects related to its diagnosis and reporting. Adv. Anat. Pathol.15(3), 127–139 (2008).
   PubMed Web of Science ®Google Scholar
• Moussa S, Yafi FA, El-Hakim A et al. Outcome of surgical treatment of patients with upper versus lower urinary tract urothelial carcinoma: stage-by-stage comparison. Urol. Int.84(1), 50–55 (2010).
   PubMedGoogle Scholar
• Siegel R, Ward E, Brawley O, Jemal A. Caner Statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J. Clin.61(4), 212–236 (2011).
   PubMed Web of Science ®Google Scholar
• Colin P, Koenig P, Ouzzane A et al. Environmental factors involved in carcinogenesis of urothelial cell carcinomas of the upper urinary tract. BJU Int.104(10), 1436–1440 (2009).
   PubMed Web of Science ®Google Scholar
• Chlapoutakis K, Theocharopoulos N, Yarmenitis S, Damilakis J. Performance of computed tomographic urography in diagnosis of upper urinary tract urothelial carcinoma, in patients presenting with hematuria: systemic review and met-analysis. Eur. J. Radiol.73(2), 334–338 (2010).
   PubMed Web of Science ®Google Scholar
• Bagley DH, Grasso M 3rd. Ureteroscopic laser treatment of upper urinary tract neoplasms. World J. Urol.28(2), 143–149 (2010).
   PubMedGoogle Scholar
• Cinman NM, Andonian S, Smith AD. Lasers in percutaneous renal procedures. World J. Urol.28(2), 135–142 (2010).
   PubMedGoogle Scholar
• Storm DW, Fulmer BR. Case report: percutaneous management of transitional-cell carcinoma of the upper urinary tract using the bipolar resectoscope. J. Endourol.21(9), 1011–1013 (2007).
   PubMed Web of Science ®Google Scholar
• O’Sullivan DC, Mynderse L, Barrett DM. Subcutaneous port for longterm access and administration of topical chemotherapy to the upper urinary tract. J. Urol.150(3), 1034–1037 (1993).
   PubMed Web of Science ®Google Scholar
• Shepherd SF, Patel A, Bidmead AM, Kellett MJ, Woodhouse CR, Dearnaley DP. Nephrostomy track brachytherapy following percutaneous resection of transitional cell carcinoma of the renal pelvis. Clin. Oncol. (R. Coll. Radiol.)7(6), 385–387 (1995).
   PubMedGoogle Scholar
• Yossepowitch O, Lifshitz DA, Dekel Y et al. Assessment of vesicoureteral reflux in patients with self-retaining ureteral stents: implications for upper urinary tract instillation. J. Urol.173(3), 890–893 (2005).
   PubMed Web of Science ®Google Scholar
• Chromecki TF, Bensalah K, Remzi M et al. Prognostic factors for upper urinary tract urothelial carcinoma. Nat Rev Urol.8(8), 440–447 (2011).
   PubMed Web of Science ®Google Scholar
• Simsir A, Sarsik B, Cureklibatir I, Sen S, Gunaydin G, Cal C. Prognostic factors for upper urinary tract urothelial carcinomas: stage, grade, and smoking status. Int. Urol. Nephrol. doi:10.1007/s11255-011-9915-z (2011) (Epub ahead of print).
   Google Scholar
• Kusuda Y, Miyake H, Terakawa T, Kondo Y, Miura T, Fujisawa M. Gender as a significant predictor of intravesical recurrence in patients with urothelial carcinoma of the upper urinary tract following nephroureterectomy. Urol Oncol. doi:10.1016/j.urolonc.2011.06.014 (2011) (Epub ahead of print).
   Google Scholar
• Kobayashi Y, Saika T, Miyaji Y, Saegusa M, Arata R, Akebi N. Preoperative positive urine cytology is a risk factor for subsequent development of bladder cancer after nephroureterectomy in patients with upper urinary tract urothelial carcinoma. World J. Urol. doi:10.1007/s00345-011-0731-y (2011) (Epub ahead of print).
   Google Scholar
• Brown GA, Busby JE, Wood CG et al. Nephroureterectomy for treating upper urinary tract transitional cell carcinoma. Time to change the treatment paradigm? BJU Int.98(6), 1176–1180 (2006).
   PubMedGoogle Scholar
• Margulis V, Shariat SF, Matin SF et al. Outcomes of radical nephroureterectomy: a series from the upper tract urothelial carcinoma collaboration. Cancer115(6), 1224–1233 (2009).
   PubMed Web of Science ®Google Scholar
• Gadzinski AJ, Roberts WW, Faerber GJ, Wolf JS Jr. Long-term outcomes of nephroureterectomy versus endoscopic management for upper tract urothelial carcinoma. J. Urol.183(6), 2148–2153 (2010).
   PubMed Web of Science ®Google Scholar
• Lee BR, Jabbour ME, Marshall FF, Smith AD, Jarrett TW. 13-year survival comparison of percutaneous and open nephroureterectomy approaches for management of transitional cell carcinoma of renal collecting system: equivalent outcomes. J. Endourol.13(4), 289–294 (1999).
   PubMed Web of Science ®Google Scholar
• Roupret M, Hupertan V, Traxer O et al. Comparison of open nephroureterectomy and ureteroscopic and percutaneous management of upper urinary tract transitional cell carcinoma. Urology67(6), 1181–1187 (2006).
   PubMed Web of Science ®Google Scholar
• Lucas SM, Svatek RS, Olgin G et al. Conservative management in selected patients with upper tract urothelial carcinoma compares favourably with early radical surgery. BJU Int.102(2), 172–176 (2008).
   PubMed Web of Science ®Google Scholar
• Rastinehead AR, Smith AD. Bacillus Calmette–Guérin for upper tract urothelial cancer: is there a role. J. Endourol.23(4), 563–568 (2009).
   PubMedGoogle Scholar
• Herr HW. Durable response of a carcinoma in situ of the renal pelvis to topical bacillus Calmette–Guérin. J. Urol.134(3), 531–532 (1985).
   PubMedGoogle Scholar
• Studer UE, Casanova G, Kraft R, Zingg EJ. Percutaneous bacillus Calmette–Guérin perfusion of the upper urinary tract for carcinoma in situ. J. Urol.142(4), 975–977 (1989).
   PubMedGoogle Scholar
• Giannarini G, Kessler TM, Birkhauser FD et al. Antegrade perfusion with bacillus calmette-guerin in patients with non-muscle invasive urothelial carcinoma of the upper urinary tract: who may benefit? Eur Urol.60(5), 955–960 (2011).
   PubMed Web of Science ®Google Scholar
• Sharpe JR, Duffy G, Chin JL. Intrarenal bacillus Calmette–Guérin therapy for upper urinary tract carcinoma in situ. J. Urol.149(3), 457–459 (1993).
   PubMedGoogle Scholar
• Yokogi H, Wada Y, Mizutani M, Igawa M, Ishibe T. Bacillus Calmette–Guérin perfusion therapy for carcinoma in situ of the upper urinary tract. Br. J. Urol.77(5), 676–679 (1996).
   PubMedGoogle Scholar
• Nishino Y, Yamamoto N, Komeda H, Takahashi Y, Deguchi T. Bacillus Calmette–Guérin instillation treatment for carcinoma in situ of the upper urinary tract. BJU Int.85(7), 799–801 (2000).
   PubMed Web of Science ®Google Scholar
• Nonomura N, Ono Y, Nozawa M et al. Bacillus Calmette–Guérin perfusion therapy for the treatment of transitional cell carcinoma in situ of the upper urinary tract. Eur. Urol.38(6), 701–704 (2000).
   PubMedGoogle Scholar
• Okubo K, Ichioka K, Terada N, Matsuta Y, Yoshimura K, Arai Y. Intrarenal bacillus Calmette–Guérin therapy for carcinoma in situ of the upper urinary tract: long-term follow-up and natural course in cases of failure. BJU Int.88(4), 343–347 (2001).
   PubMed Web of Science ®Google Scholar
• Irie A, Iwamura M, Kadowaki K, Ohkawa A, Uchida T, Baba S. Intravesical instillation of bacille Calmette–Guérin for carcinoma in situ of the urothelium involving the upper urinary tract using vesicoureteral reflux created by a double-pigtail catheter. Urology59(1), 53–57 (2002).
   PubMed Web of Science ®Google Scholar
• Miyake H, Eto H, Hara S, Okada H, Kamidono S, Hara I. Clinical outcome of bacillus Calmette–Guérin perfusion therapy for carcinoma in situ of the upper urinary tract. Int. J. Urol.9(12), 677–680 (2002).
   PubMed Web of Science ®Google Scholar
• Hayashida Y, Nomata K, Noguchi M, Eguchi J, Koga S, Yamashita S et al. Long-term effects of bacille Calmette–Guérin perfusion therapy for treatment of transitional cell carcinoma in situ of upper urinary tract. Urology63(6), 1084–1088 (2004).
   PubMed Web of Science ®Google Scholar
• Kojima Y, Tozawa K, Kawai N, Sasaki S, Hayashi Y, Kohri K. Long-term outcome of upper urinary tract carcinoma in situ: effectiveness of nephroureterectomy versus bacillus Calmette–Guérin therapy. Int. J. Urol.13(4), 340–344 (2006).
   PubMed Web of Science ®Google Scholar
• Herr HW, Pinsky CM, Whitmore WF Jr, Sogani PC, Oettgen HF, Melamed MR. Long-term effect of intravesical bacillus Calmette–Guérin on flat carcinoma in situ of the bladder. J. Urol.135(2), 265–267 (1986).
   PubMed Web of Science ®Google Scholar
• Schoenberg MP, Van Arsdalen KN, Wein AJ. The management of transitional cell carcinoma in solitary renal units. J. Urol.146(3), 700–702 (1991).
   PubMed Web of Science ®Google Scholar
• Jarrett TW, Sweetser PM, Weiss GH, Smith AD. Percutaneous management of transitional cell carcinoma of the renal collecting system: 9-year experience. J. Urol.154(5), 1629–1635 (1995).
   PubMed Web of Science ®Google Scholar
• Patel A, Fuchs GJ. New techniques for the administration of topical adjuvant therapy after endoscopic ablation of upper urinary tract transitional cell carcinoma. J. Urol.159(1), 71–75 (1998).
   PubMed Web of Science ®Google Scholar
• Clark PE, Streem SB, Geisinger MA. 13-year experience with percutaneous management of upper tract transitional cell carcinoma. J. Urol.161(3), 772–775 (1999).
   PubMed Web of Science ®Google Scholar
• Liatsikos EN, Dinlenc CZ, Kapoor R, Smith AD. Transitional-cell carcinoma of the renal pelvis: ureteroscopic and percutaneous approach. J. Endourol.15(4), 377–383 (2001).
   PubMed Web of Science ®Google Scholar
• Rastinehead AR, Ost MC, Vanderbrink BA et al. A 20-year experience with percutaneous resection of upper tract transitional carcinoma: is there an oncologic benefit with adjuvant bacillus Calmette Guérin therapy? Urology73(1), 27–31 (2009).
   PubMedGoogle Scholar
• Elliott D, Blute M, Patterson D, Bergstralh E, Segura J. Long-term follow-up of endoscopically treated upper urinary tract transitional cell carcinoma. Urology47(6), 819–825 (1996).
   PubMed Web of Science ®Google Scholar
• Martinez-Pineiro JA, Garcia Matres MJ, Martinez-Pineiro L. Endourological treatment of upper tract urothelial carcinomas: analysis of a series of 59 tumors. J. Urol.156(2 Pt 1), 377–385 (1996).
   PubMed Web of Science ®Google Scholar
• Keeley FX Jr, Bagley DH. Adjuvant mitomycin C following endoscopic treatment of upper tract transitional cell carcinoma. J. Urol.158(6), 2074–2077 (1997).
   PubMed Web of Science ®Google Scholar
• See WA. Continuous antegrade infusion of adriamycin as adjuvant therapy for upper tract urothelial malignancies. Urology.56(2), 216–222 (2000).
   PubMed Web of Science ®Google Scholar
• Burns JA, Williams RD, Hedican SP, O’Donnell MA. The treatment of upper tract transitional cell carcinoma with BCG plus interferon-alpha. Proceedings of: The North Central Section of the American Urological Association Annual Meeting. Cancun, Mexico, 22–27 October 2001.
   Google Scholar
• Katz MH, Lee MW, Gupta M. Setting a new standard for topical therapy of upper-tract transitional-cell carcinoma: BCG and interferon alpha2B. J. Endourol.21(4), 374–377 (2007).
   PubMedGoogle Scholar
• Goel MC, Mahendra V, Roberts JG. Percutaneous management of renal pelvic urothelial tumors: long-term followup. J. Urol.169(3), 925–929 (2003).
   PubMed Web of Science ®Google Scholar
• Palou J, Piovesan LF, Huguet J, Salvador J, Vicente J, Villavicencio H. Percutaneous nephroscopic management of upper tract transitional cell carcinoma: recurrence and long-term followup. J. Urol.172(1), 66–69 (2004).
   PubMed Web of Science ®Google Scholar
• Binsaleh S, Sircar K, Elhilali M, Anidjar M. BCG for upper-tract transitional-cell carcinoma: is it safe in patients with renal compromise? J. Endourol.20(12), 1068–1071 (2006).
   PubMedGoogle Scholar
• Raymundo EM, Lipkin ME, Banez LB et al. Third prize: the role of endoscopic nephron-sparing surgery in the management of upper tract urothelial carcinoma. J. Endourol.25(3), 377–384 (2011).
   PubMed Web of Science ®Google Scholar
• Jabbour ME, Smith AD. Primary percutaneous approach to upper urinary tract transitional cell carcinoma. Urol. Clin. North Am.27(4), 739–750 (2000).
   PubMed Web of Science ®Google Scholar
• Jabbour ME, Desgrandchamps F, Cazin S, Teillac P, Le Duc A, Smith AD. Percutaneous management of grade II upper urinary tract transitional cell carcinoma: the long-term outcome. J. Urol.163(4), 1105–1107 (2000).
   PubMed Web of Science ®Google Scholar
• Soderdahl DW, Fabrizio MD, Rahman NU, Jarrett TW, Bagley DH. Endoscopic treatment of upper tract transitional cell carcinoma. Urol. Oncol.23(2), 114–122 (2005).
   PubMed Web of Science ®Google Scholar
• Painter DJ, Denton K, Timoney AG, Keeley FX. Ureteroscopic management of upper-tract urothelial cancer: an exciting nephron-sparing option or an unacceptable risk? J. Endourol.22(6), 1237–1239 (2008).
   PubMed Web of Science ®Google Scholar
• Gurbuz C, Youssef RF, Shariat SF et al. The impact of previous ureterosopcic tumor ablation on oncologic outcomes after radical nephroureterectomy for upper tract urothelial carcinoma. J. Endourol.25(5), 775–779 (2011).
   PubMed Web of Science ®Google Scholar
• Tavora F, Fajardo DA, Lee TK et al. Small endoscopic biopsies of the ureter and renal pelvis: pathologic pitfalls. Am. J. Surg. Pathol.33(10), 1540–1546 (2009).
   PubMed Web of Science ®Google Scholar
• Keeley FX, Kulp DA, Bibbo M, McCue PA, Bagley DH. Diagnostic accuracy of ureteroscopic biopsy in upper tract transitional cell carcinoma. J. Urol.157(1), 33–37 (1997).
   PubMed Web of Science ®Google Scholar
• Gadzinski AJ, Roberts WW, Faerber GJ et al. Long-term outcomes of immediate versus delayed nephroureterectomy for upper tract urothelial carcinoma. J. Endourol. doi:10.1089/end.2011.0220 (2011) (Epub ahead of print).
   PubMedGoogle Scholar
• Fritsche HM, Novara G, Burger M et al. Macroscopic sessile tumor architecture is a pathologic feature of biologically aggressive upper tract urothelial carcinoma. Urol. Oncol. doi:10.1016/j.urolonc.2010.07.010 (2011) (Epub ahead of print).
   Google Scholar
• Otto W, Shariat SF, Fritsche HM et al. Concomitant carcinoma in situ as an independent prognostic parameter for recurrence and survival in upper tract urothelial carcinoma: a multicenter analysis of 772 patients. World J. Urol.29, 487–494 (2011).
   PubMed Web of Science ®Google Scholar
• Raman JD, Ng CK, Scherr DS et al. Impact of tumor location on prognosis for patients with upper tract urothelial carcinoma managed by radical nephroureterectomy. Eur. Urol.57(6), 1072–1079 (2010).
   PubMed Web of Science ®Google Scholar
• Favaretto RL, Shariat SF, Chade DC et al. The effect of tumor location on prognosis in patients treated with radical nephroureterectomy at Memorial Sloan–Kettering Cancer Center. Eur. Urol.58(4), 574–580 (2010).
   PubMed Web of Science ®Google Scholar